Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 8/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721792 | 0.87 | NOD2 (0.39) | NOD2ABCB1HDAC1 | |
| SCHEMBL3725541 | 0.87 | FAAH (0.37) | CCR5UBE2MDCUN1D1KCNH2 | |
| SCHEMBL3720201 | 0.86 | CCNE1 (0.38) | HDAC1GSK3AGSK3BROCK2KLKB1 | |
| SCHEMBL3721600 | 0.86 | CCNE1 (0.38) | HDAC1GSK3AGSK3BROCK2KLKB1 | |
| SCHEMBL3720947 | 0.86 | NR3C1 (0.35) | CCR5UBE2MDCUN1D1LMNA | |
| SCHEMBL3716735 | 0.86 | TYK2 (0.34) | CCR5TRPV1 | |
| SCHEMBL3716732 | 0.86 | TYK2 (0.34) | CCR5TRPV1 | |
| SCHEMBL13745149 | 0.85 | PIK3CA (0.36) | TRPV1 | |
| SCHEMBL13013622 | 0.85 | PIK3CA (0.36) | TRPV1 | |
| SCHEMBL3723311 | 0.85 | MALT1 (0.37) | CCR5UBE2MDCUN1D1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240488-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2240488-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009100375-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP4K2, MAP3K15 | NOD2 3749/4885CCR5 3896/4885UBE2M 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.